Gossamer Bio EVP granted 2.9M options at $0.18
Gossamer Bio, Inc. (GOSS) reported that executive officer Christian Waage, EVP, Tech Ops and Admin, received a grant of stock options covering 2,900,026 shares of common stock at an exercise price of $0.175 per share.
Rhea-AI Filing Summary
Gossamer Bio, Inc. (GOSS) reported that executive officer Christian Waage, EVP, Tech Ops and Admin, received a grant of stock options covering 2,900,026 shares of common stock at an exercise price of $0.175 per share. The options expire on 2036-08-23 and vest based on future milestones and service conditions tied to FDA approval of seralutinib or, if approval is delayed, over time following the second anniversary of the grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 2,900,026 shares
Grant/Award
1 txn
Insider
Christian Waage
Role
EVP, Tech Ops and Admin
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 2,900,026 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 2,900,026 contracts (Direct)
Footnotes (1)
- F1. 50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Key Figures
Stock options granted: 2,900,026 option shares
Exercise price: $0.175 per share
Total option shares following transaction: 2,900,026 option shares
+3 more
6 metrics
Stock options granted
2,900,026 option shares
Grant of Stock Option (Right to Buy) reported for 2026-08-24
Exercise price
$0.175 per share
Conversion or exercise price for the stock option grant
Total option shares following transaction
2,900,026 option shares
Total derivative holdings after the reported grant
Option expiration date
2036-08-23
Expiration date of the reported stock option award
Initial vesting on FDA approval
50% of option shares
Vests upon FDA approval of seralutinib, subject to continuous service
Subsequent vesting installments
1/24 of remaining 50% monthly
Vests on last day of each one-month period after FDA approval or, if no approval within two years, after the two-year date
Key Terms
Stock Option (Right to Buy), exercise price, vesting, FDA approval, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: "0.1750""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares subject to the option will vest upon FDA approval"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FDA approval medical
"will vest upon FDA approval of seralutinib"
FDA approval is the U.S. Food and Drug Administration’s formal authorization for a drug, vaccine, or medical device to be marketed and sold after reviewers determine it meets standards for safety and effectiveness. For investors it’s a pivotal milestone because it opens the door to legal, large-scale sales and can sharply boost revenue potential while reducing regulatory uncertainty—like receiving a safety certificate that lets a new bridge carry traffic and tolls.
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer"
FAQ
What insider transaction did GOSS disclose for Christian Waage?
Gossamer Bio disclosed that Christian Waage, EVP, Tech Ops and Admin, received a grant of 2,900,026 stock options to purchase common stock, reported as an acquisition under transaction code A. The options were granted at an exercise price of $0.175 per share.
What is the exercise price of the new GOSS stock options granted to Christian Waage?
The granted stock options have an exercise price of $0.175 per share. Each option allows the purchase of one share of Gossamer Bio common stock at this price, subject to the vesting conditions described in the award footnote.
When do Christian Waage’s GOSS stock options expire?
The stock options granted to Christian Waage expire on 2036-08-23. They remain exercisable until that expiration date, subject to earlier termination under their terms and to the vesting conditions tied to FDA approval milestones and continued service.
What are the vesting conditions for the new GOSS stock options tied to seralutinib?
The footnote states that 50% of the option shares vest upon FDA approval of seralutinib. The remaining 50% then vests in 24 equal monthly installments. If FDA approval has not occurred within two years of grant, vesting instead occurs in 24 equal monthly installments starting two years after grant, in each case subject to continuous service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
